NFE2L2 and pancreatic neoplasm: Gemcitabine sensitivity can be obtained by inhibition of NRF2 by PIK-75 [200], which is supported by knockdown of NRF2 by siRNA in pancreatic cancer cell lines MIAPaCa-2, AsPc-1, and Panc-28 cells [201].